Pharvaris N.V. (PHVS) Form 6-K — Aug 12, 2026
Pharvaris reported a second-quarter 2026 net loss of €47.8 million, or €0.70 per share, versus a €45.5 million loss (€0.83 per share) a year earlier, as R&D expenses rose 18% to €35.0 million and G&A jumped 47% to €15.8 million on commercial launch preparation. The company ended the quarter with €318 million in cash and equivalents, bolstered by a May 2026 underwritten offering of $132.3 million in shares led by Morgan Stanley and Leerink Partners, which management says extends its cash runway into 2028.
Key figures
- Eps
- -€0.70 (Q2 2026) / -€1.31 (H1 2026)
- Net Income
- -€47.8 million (Q2 2026) / -€87.0 million (H1 2026)
- Total Assets
- €328.7 million as of June 30, 2026
- Cash Position
- €318.3 million as of June 30, 2026 (vs €291.7 million at December 31, 2025)
- Gross Proceeds
- $132.3 million gross (May 2026 offering); €105.7 million ($124.3 million) net after €6.7 million ($7.9 million) fees
- Shares Offered
- 4455863
- Shares Outstanding
- 70204506
- Pdufa Date
- April 23, 2027
- Cash Runway
- into 2028
- Ga Expense Q2
- €15.8 million, +47% YoY
- Rd Expense Q2
- €35.0 million, +18% YoY
- Chapter3 Topline Timing
- 3Q2026 (by September 30, 2026)
- Contractual Obligations
- €118 million
- Total Operating Expense Q2
- €50.8 million, +26% YoY
- Net Cash Used In Operating H1
- €86.6 million
- Chapter3 Participants Randomized
- 85
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.